KR20080016789A - 혈액 림프구에서 자궁내막증을 진단할 수 있는 분자마커의동정 - Google Patents
혈액 림프구에서 자궁내막증을 진단할 수 있는 분자마커의동정 Download PDFInfo
- Publication number
- KR20080016789A KR20080016789A KR1020077021464A KR20077021464A KR20080016789A KR 20080016789 A KR20080016789 A KR 20080016789A KR 1020077021464 A KR1020077021464 A KR 1020077021464A KR 20077021464 A KR20077021464 A KR 20077021464A KR 20080016789 A KR20080016789 A KR 20080016789A
- Authority
- KR
- South Korea
- Prior art keywords
- endometriosis
- gene expression
- gene
- peripheral blood
- overexpressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 124
- 210000004698 lymphocyte Anatomy 0.000 title description 16
- 230000014509 gene expression Effects 0.000 claims abstract description 158
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 154
- 238000000034 method Methods 0.000 claims abstract description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 36
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 31
- 239000011886 peripheral blood Substances 0.000 claims abstract description 31
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 27
- 238000005259 measurement Methods 0.000 claims abstract description 25
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 claims description 29
- 102100021958 Lysyl oxidase homolog 1 Human genes 0.000 claims description 29
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 25
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 238000004458 analytical method Methods 0.000 claims description 23
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 102100021763 Alpha-mannosidase 2x Human genes 0.000 claims description 20
- 101000615966 Homo sapiens Alpha-mannosidase 2x Proteins 0.000 claims description 20
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 17
- 239000002299 complementary DNA Substances 0.000 claims description 15
- 238000003757 reverse transcription PCR Methods 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 101100189590 Mus musculus Pde6b gene Proteins 0.000 claims description 10
- 238000010208 microarray analysis Methods 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims 1
- 101000614345 Homo sapiens Prolyl 4-hydroxylase subunit alpha-1 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 102100040477 Prolyl 4-hydroxylase subunit alpha-1 Human genes 0.000 claims 1
- 239000000523 sample Substances 0.000 description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 201000010099 disease Diseases 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 35
- 229920001184 polypeptide Polymers 0.000 description 33
- 150000007523 nucleic acids Chemical class 0.000 description 27
- 238000003752 polymerase chain reaction Methods 0.000 description 25
- 108020004707 nucleic acids Proteins 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 102000001770 Low Density Lipoprotein Receptor-Related Protein-5 Human genes 0.000 description 19
- 108010015167 Low Density Lipoprotein Receptor-Related Protein-5 Proteins 0.000 description 19
- 238000002493 microarray Methods 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 18
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 16
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 16
- 238000003753 real-time PCR Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000000018 DNA microarray Methods 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 102100040682 Platelet-derived growth factor D Human genes 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 101000611892 Homo sapiens Platelet-derived growth factor D Proteins 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 9
- 238000010839 reverse transcription Methods 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 7
- 230000027758 ovulation cycle Effects 0.000 description 6
- -1 α-2-actin) Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000002357 endometrial effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000003630 growth substance Substances 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 231100000535 infertility Toxicity 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000002357 laparoscopic surgery Methods 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000005168 endometrial cell Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 101710189311 Cytokine receptor common subunit gamma Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108010000837 Janus Kinase 1 Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100035071 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 201000002595 endometriosis of ovary Diseases 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000033065 inborn errors of immunity Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 208000030747 ovarian endometriosis Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 102100037513 40S ribosomal protein S23 Human genes 0.000 description 1
- 101710131793 40S ribosomal protein S23 Proteins 0.000 description 1
- 101000983256 Acanthamoeba polyphaga mimivirus Putative prolyl 4-hydroxylase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100037080 C4b-binding protein beta chain Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000280 DNA damage induction Toxicity 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101150040913 DUT gene Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004240 Glycodelin Human genes 0.000 description 1
- 108010081520 Glycodelin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 1
- 102100031153 Growth arrest and DNA damage-inducible protein GADD45 beta Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000740689 Homo sapiens C4b-binding protein beta chain Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101001066164 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 beta Proteins 0.000 description 1
- 101000611643 Homo sapiens Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 108010054377 Mannosidases Proteins 0.000 description 1
- 102000001696 Mannosidases Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 101710170209 Platelet-derived growth factor D Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000015766 Protein Kinase C beta Human genes 0.000 description 1
- 108010024526 Protein Kinase C beta Proteins 0.000 description 1
- 102100040714 Protein phosphatase 1 regulatory subunit 15A Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010051611 Signal Recognition Particle Proteins 0.000 description 1
- 102000013598 Signal recognition particle Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007691 collagen metabolic process Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 108010072285 growth inhibitory proteins Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010000633 signal peptide receptor Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65433105P | 2005-02-18 | 2005-02-18 | |
| US60/654,331 | 2005-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080016789A true KR20080016789A (ko) | 2008-02-22 |
Family
ID=36182367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077021464A Withdrawn KR20080016789A (ko) | 2005-02-18 | 2005-12-09 | 혈액 림프구에서 자궁내막증을 진단할 수 있는 분자마커의동정 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090208939A1 (enExample) |
| EP (1) | EP1848818A1 (enExample) |
| JP (1) | JP2008537474A (enExample) |
| KR (1) | KR20080016789A (enExample) |
| CN (1) | CN101124340A (enExample) |
| AU (1) | AU2005327929A1 (enExample) |
| BR (1) | BRPI0520012A2 (enExample) |
| CA (1) | CA2596932A1 (enExample) |
| IL (1) | IL184920A0 (enExample) |
| MX (1) | MX2007009562A (enExample) |
| NO (1) | NO20074762L (enExample) |
| WO (1) | WO2006091254A1 (enExample) |
| ZA (1) | ZA200707752B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101333207B1 (ko) * | 2011-07-13 | 2013-11-26 | 부산대학교 산학협력단 | 자궁내막증과 연관된 유전자 마커 및 이의 용도 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9222938B2 (en) * | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
| WO2008123901A2 (en) * | 2007-02-06 | 2008-10-16 | Genizon Biosciences | Genemap of the human genes associated with endometriosis |
| US8932993B1 (en) | 2007-06-11 | 2015-01-13 | Juneau Biosciences, LLC. | Method of testing for endometriosis and treatment therefor |
| WO2009140126A1 (en) * | 2008-05-14 | 2009-11-19 | Juneau Biosciences, Llc | Method of administering a therapeutic |
| WO2010124101A2 (en) | 2009-04-22 | 2010-10-28 | Juneau Biosciences, Llc | Genetic markers associated with endometriosis and use thereof |
| JP5503942B2 (ja) * | 2009-10-30 | 2014-05-28 | シスメックス株式会社 | 疾患の罹患の判定方法 |
| EP2348129A1 (en) * | 2010-01-21 | 2011-07-27 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
| US11180807B2 (en) | 2011-11-04 | 2021-11-23 | Population Bio, Inc. | Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease |
| EP2812452B1 (en) | 2012-02-09 | 2020-05-27 | Population Bio, Inc. | Methods and compositions for screening and treating developmental disorders |
| KR101445560B1 (ko) | 2012-05-10 | 2014-09-29 | 한국수력원자력 주식회사 | 저준위 전리방사선에 민감한 유전자 검출 방법 및 상기 방법으로 검출된 유전자 |
| WO2014043519A1 (en) | 2012-09-14 | 2014-03-20 | Population Diagnostics Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
| US9434991B2 (en) | 2013-03-07 | 2016-09-06 | Juneau Biosciences, LLC. | Method of testing for endometriosis and treatment therefor |
| US20160244834A1 (en) * | 2013-06-28 | 2016-08-25 | Acumen Research Laboratories Pte. Ltd. | Sepsis biomarkers and uses thereof |
| DK2891722T3 (en) | 2013-11-12 | 2019-01-07 | Population Bio Inc | METHODS AND COMPOSITIONS FOR DIAGNOSTICING, PROGRAMMING AND TREATMENT OF ENDOMETRIOSIS |
| DE102014203235A1 (de) * | 2014-02-24 | 2015-08-27 | Mahle International Gmbh | Klimagerät, insbesondere für ein Kraftfahrzeug und Verfahren zur Herstellung einer Komponente eines Klimagerätes |
| RU2558854C1 (ru) * | 2014-06-23 | 2015-08-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Способ прогнозирования риска развития эндометриоза |
| JP2016077234A (ja) * | 2014-10-17 | 2016-05-16 | 国立大学法人鳥取大学 | 子宮内膜症の早期診断のための診断キット、診断マーカー及び検出方法 |
| CN107326065B (zh) * | 2016-04-29 | 2022-07-29 | 博尔诚（北京）科技有限公司 | 一种基因标识物的筛选方法及其应用 |
| CN107858415B (zh) * | 2016-09-19 | 2021-05-28 | 深圳华大生命科学研究院 | 用于子宫腺肌症检测的生物标志物组合及其应用 |
| US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
| US10729693B2 (en) * | 2018-03-02 | 2020-08-04 | Ponce Medical School Foundation, Inc. | Compositions and methods for the treatment of endometriosis |
| CN108456723A (zh) * | 2018-03-21 | 2018-08-28 | 福州福瑞医学检验实验室有限公司 | 一种子宫内膜异位症风险预测的基因检测引物和试剂盒 |
| JP2021521803A (ja) * | 2018-04-20 | 2021-08-30 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 子宮内膜症の治療のための組成物および方法 |
| US11906529B1 (en) * | 2018-04-27 | 2024-02-20 | Marshall University Research Corporation | Methods for treatment and diagnosis of endometriosis |
| FI4417708T3 (fi) | 2018-08-08 | 2025-12-04 | Pml Screening Llc | Menetelmiä virustaudin kehittymisen riskin arvioimiseksi geneettisen testin avulla |
| WO2024263816A2 (en) * | 2023-06-21 | 2024-12-26 | Cristcot Llc | Development and validation of the hemorrhoid disease symptom impact measure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1537243B1 (en) * | 2002-08-30 | 2008-05-28 | Oncotherapy Science, Inc. | Method of diagnosing ovarian endometriosis |
-
2005
- 2005-12-09 BR BRPI0520012-1A patent/BRPI0520012A2/pt not_active Application Discontinuation
- 2005-12-09 MX MX2007009562A patent/MX2007009562A/es not_active Application Discontinuation
- 2005-12-09 US US11/884,402 patent/US20090208939A1/en not_active Abandoned
- 2005-12-09 WO PCT/US2005/044723 patent/WO2006091254A1/en not_active Ceased
- 2005-12-09 KR KR1020077021464A patent/KR20080016789A/ko not_active Withdrawn
- 2005-12-09 CN CNA2005800484494A patent/CN101124340A/zh active Pending
- 2005-12-09 CA CA002596932A patent/CA2596932A1/en not_active Abandoned
- 2005-12-09 JP JP2007556134A patent/JP2008537474A/ja not_active Withdrawn
- 2005-12-09 AU AU2005327929A patent/AU2005327929A1/en not_active Abandoned
- 2005-12-09 EP EP05853605A patent/EP1848818A1/en not_active Withdrawn
-
2007
- 2007-07-30 IL IL184920A patent/IL184920A0/en unknown
- 2007-09-11 ZA ZA200707752A patent/ZA200707752B/xx unknown
- 2007-09-18 NO NO20074762A patent/NO20074762L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101333207B1 (ko) * | 2011-07-13 | 2013-11-26 | 부산대학교 산학협력단 | 자궁내막증과 연관된 유전자 마커 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006091254A1 (en) | 2006-08-31 |
| CA2596932A1 (en) | 2006-08-31 |
| JP2008537474A (ja) | 2008-09-18 |
| IL184920A0 (en) | 2007-12-03 |
| EP1848818A1 (en) | 2007-10-31 |
| BRPI0520012A2 (pt) | 2009-04-14 |
| MX2007009562A (es) | 2008-03-11 |
| ZA200707752B (en) | 2010-05-26 |
| AU2005327929A1 (en) | 2006-08-31 |
| US20090208939A1 (en) | 2009-08-20 |
| CN101124340A (zh) | 2008-02-13 |
| NO20074762L (no) | 2007-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080016789A (ko) | 혈액 림프구에서 자궁내막증을 진단할 수 있는 분자마커의동정 | |
| CN107099581B (zh) | 预测、诊断和治疗特发性肺纤维化的方法 | |
| EP2742155B1 (en) | Biomarker for alzheimer's disease and/or mild cognitively impairment | |
| US9803243B2 (en) | Biomarkers for diagnosis of stroke and its causes | |
| US11136626B2 (en) | Biomarkers for the diagnosis of lacunar stroke | |
| US20190233893A1 (en) | Methods of diagnosing endometriosis | |
| US20110166028A1 (en) | Methods for predicting treatment response based on the expression profiles of biomarker genes in notch mediated cancers | |
| US20160003837A1 (en) | Biomarkers for the prediction of preterm birth | |
| JP7463351B2 (ja) | 脳卒中の血液バイオマーカー | |
| EP3015864A1 (en) | Biomarkers for the diagnosis and the response to treatment of pancreatic cancer | |
| Evans et al. | In the secretory endometria of women, luminal epithelia exhibit gene and protein expressions that differ from those of glandular epithelia | |
| US20120213769A1 (en) | Methods of diagnosing amyotrophic lateral sclerosis (als) | |
| JP2013535688A (ja) | 肝移植における寛容性の診断及び／又は予後のための方法およびキット | |
| Flores et al. | Identification of molecular markers for endometriosis in blood lymphocytes by using deoxyribonucleic acid microarrays | |
| KR101657051B1 (ko) | 만성폐쇄성폐질환 진단용 마커 조성물 | |
| WO2011109810A2 (en) | Methods of predicting high grade gliomas using senescence associated genes | |
| JP2012532623A (ja) | スクリーニング法 | |
| US20130217656A1 (en) | Methods and compositions for diagnosing and treating lupus | |
| CN116287180A (zh) | 检测标志物的试剂在制备用于诊断哮喘的试剂盒中的应用 | |
| TW200940990A (en) | A diagnostic blood test for psychosis | |
| KR20100070776A (ko) | 습관성 유산 진단용 바이오마커 | |
| JP2003235557A (ja) | 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法 | |
| Merino-Zamorano et al. | Identification of plasma biomarkers of human intracerebral hemorrhage subtypes through microarray technology | |
| RU2719411C1 (ru) | Способ определения предрасположенности к нарушению репродуктивной функции у женщин в условиях избыточной контаминации фенолом | |
| US20120004122A1 (en) | Diagnostic Marker for Migraine and Use Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20070918 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |